PeptiDream Inc (4587)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PeptiDream Inc (4587) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013468
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform. Its technologies include flexizyme; translation, cyclization, and peptide modifying technologies; and PD display. PeptiDream’s technologies enables the production of peptide libraries for the development of peptide-based products. It offers products for the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and others. The company collaborates with other biotechnology and drug development companies to receive contracts and research and development support funds, and target proteins. PeptiDream is headquartered in Kawasaki, Japan.

PeptiDream Inc (4587) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PeptiDream Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PeptiDream Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
PeptiDream to Acquire Drug Discovery Research Business from PharmaDesign 12
Private Equity 13
Taiyo Pacific Partners Acquires Minority Stake in PeptiDream 13
Partnerships 14
Bayer and PeptiDream Enter into Partnership 14
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 17
PeptiDream Enters into Agreement with Janssen Pharma 18
PeptiDream Enters into Research Agreement with BIND Therapeutics 19
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 20
PeptiDream Enters into Agreement with Genentech 21
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 22
Teijin Pharma Enters into Discovery Agreement with PeptiDream 23
PeptiDream Enters into Discovery Agreement with Sanofi 24
PeptiDream Enters into Peptide Discovery Agreement with Merck 25
PeptiDream Expands Drug Discovery Agreement with Novartis 26
PeptiDream Enters into Agreement with Tokyo Metropolitan Institute of Medical Science 27
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 28
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 29
PeptiDream Expands Drug Discovery Agreement with Amgen 30
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 31
PeptiDream Enters into Drug Discovery Agreement with MedImmune 32
PeptiDream Extends Discovery Agreement With Bristol-Myers Squibb 33
PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 34
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 35
Licensing Agreements 36
Eli Lilly Enters into Licensing Agreement with PeptiDream 36
Shionogi Enters into Licensing Agreement with PeptiDream 37
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 38
PeptiDream Exercises Option for Licensing Agreement with Novartis 39
PeptiDream Enters Into Licensing Agreement With Eli Lilly 40
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 41
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 42
Equity Offering 43
PeptiDream Raises USD53 Million in IPO 43
PeptiDream Inc – Key Competitors 44
PeptiDream Inc – Key Employees 45
PeptiDream Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Corporate Communications 47
Aug 22, 2017: PeptiDream Appoints Representative Directors 47
Product News 48
12/16/2016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer 48
Other Significant Developments 49
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck 49
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin 50
May 31, 2017: PeptiDream Announces 5 th Milestone from Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb 51
Mar 22, 2017: PeptiDream Announces 1st Milestone from Macrocyclic Peptide Drug Discovery Alliance with Shionogi 52
Feb 14, 2017: PeptiDream Announces the Selection of Development Candidate from Discovery Collaboration with Daiichi Sankyo 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
PeptiDream Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PeptiDream Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PeptiDream Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PeptiDream to Acquire Drug Discovery Research Business from PharmaDesign 12
Taiyo Pacific Partners Acquires Minority Stake in PeptiDream 13
Bayer and PeptiDream Enter into Partnership 14
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 17
PeptiDream Enters into Agreement with Janssen Pharma 18
PeptiDream Enters into Research Agreement with BIND Therapeutics 19
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 20
PeptiDream Enters into Agreement with Genentech 21
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 22
Teijin Pharma Enters into Discovery Agreement with PeptiDream 23
PeptiDream Enters into Discovery Agreement with Sanofi 24
PeptiDream Enters into Peptide Discovery Agreement with Merck 25
PeptiDream Expands Drug Discovery Agreement with Novartis 26
PeptiDream Enters into Agreement with Tokyo Metropolitan Institute of Medical Science 27
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 28
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 29
PeptiDream Expands Drug Discovery Agreement with Amgen 30
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 31
PeptiDream Enters into Drug Discovery Agreement with MedImmune 32
PeptiDream Extends Discovery Agreement With Bristol-Myers Squibb 33
PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 34
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 35
Eli Lilly Enters into Licensing Agreement with PeptiDream 36
Shionogi Enters into Licensing Agreement with PeptiDream 37
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 38
PeptiDream Exercises Option for Licensing Agreement with Novartis 39
PeptiDream Enters Into Licensing Agreement With Eli Lilly 40
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 41
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 42
PeptiDream Raises USD53 Million in IPO 43
PeptiDream Inc, Key Competitors 44
PeptiDream Inc, Key Employees 45
PeptiDream Inc, Other Locations 46

★海外企業調査レポート[PeptiDream Inc (4587)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Qatar Airways Group Q.C.S.C.
    Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report Summary Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Intas Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropo …
  • NIKE Inc:戦略・SWOT・企業財務分析
    NIKE Inc - Strategy, SWOT and Corporate Finance Report Summary NIKE Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Bon Secours Health System Inc:企業の戦略的SWOT分析
    Bon Secours Health System Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • PetroRio SA (PRIO3):企業の財務・戦略的SWOT分析
    Summary PetroRio SA (PetroRio), formerly HRT Participacoes em Petroleo SA, a subsidiary of HRT Oil & Gas Ltd, is oil and gas company. It offers investment and recovering of oil production assets. The company provides development of solid growth platforms aiming to generate value to its shareholders …
  • Zoo Digital Group plc (ZOO):企業の財務・戦略的SWOT分析
    Summary Zoo Digital Group Plc (ZOO) is a technology company that offers localization and media production services. It offers services such as subtitling, captioning, dubbing and digital distribution. The company's activities include providing a range of services to allow television and movie conten …
  • Galaxy Entertainment Group Ltd:企業の戦略・SWOT・財務分析
    Galaxy Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Galaxy Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Meketa Investment Group:企業の戦略・SWOT・財務情報
    Meketa Investment Group - Strategy, SWOT and Corporate Finance Report Summary Meketa Investment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Mitsui Chemicals, Inc.:企業の戦略・SWOT・財務分析
    Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Toei Animation Co., Ltd.:企業の戦略・SWOT・財務分析
    Toei Animation Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toei Animation Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Ambry Genetics Corp:医療機器:M&Aディール及び事業提携情報
    Summary Ambry Genetics Corp (Ambry Genetics), a subsidiary of Konica Minolta Inc, is a provider of clinical genetic testing services. The company provides genetic diagnosis for various conditions including hereditary cancer, epilepsy, hereditary cardiovascular disease and neurodevelopmental disorder …
  • Mastech Digital Inc (MHH):企業の財務・戦略的SWOT分析
    Summary Mastech Digital Inc (Mastech) operates as an IT staffing company that offers digital transformation services. The company offers services such as database administration, middleware, business analytics and QA, data warehousing, admin desktop fiac, and project management services, among other …
  • Bourbon Corporation:企業の戦略・SWOT・財務情報
    Bourbon Corporation - Strategy, SWOT and Corporate Finance Report Summary Bourbon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Birla Corporation Ltd:企業の戦略・SWOT・財務情報
    Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Enlivant Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Enlivant Inc (Enlivant) is an assisted living facilities provider that offers senior living residence services. The center provides senior housing options, choosing assisted living and short term stay services. It also provides attentive and individualized care services. Enlivant offers assi …
  • 3D Oil Ltd (TDO):石油・ガス:M&Aディール及び事業提携情報
    Summary 3D Oil Ltd (3D Oil) is a producer and developer of oil and gas properties. The company’s products include natural gas and crude oil. It has interest in exploration permits in the offshore Gippsland and Otway Basins of South East Australia. 3D Oil's projects include T49-P located in offshore …
  • Hotels.com LP:企業の戦略・SWOT・財務情報
    Hotels.com LP - Strategy, SWOT and Corporate Finance Report Summary Hotels.com LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Medicines for Malaria Venture:製薬・医療:M&Aディール及び事業提携情報
    Summary Medicines for Malaria Venture (MMV) is a drug developing company that discovers and delivers new, effective and affordable antimalarial drugs. The center provides products that offers efficacy against drug-resistant strains of plasmodium falciparum, potential for intermittent treatments, saf …
  • Virgin Money PLC:企業の戦略的SWOT分析
    Virgin Money PLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Heron Therapeutics Inc (HRTX):企業の財務・戦略的SWOT分析
    Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆